Abstract. The BCR-ABL1 induces chronic myelogenous leukemia (CML) and Ph + acute lymphoblastic leukemia (ALL). Recent studies revealed high ratios of loss of the IKZF1 gene which encodes IKAROS in BCR-ABL1 + ALL and lymphoblastic crisis (LBC) of CML. However, little is known about the cooperativity between the aberrant IKAROS and BCR-ABL1 in primary human hematopoietic cells. We investigated the effects of expression of BCR-ABL1 and/or IK6, a natural dominant negative isoform of IKAROS, on proliferation and differentiation of human CD34
Introduction
The BCR-ABL1 fusion gene, which originates from a reciprocal translocation between chromosome 9q34 and 22q11, is closely involved in chronic myelogenous leukemia (CML) and a subgroup of acute lymphoblastic leukemia (ALL). p190
BCR-ABL1 is found almost exclusively in BCR-ABL1 + ALL, whereas p210
BCR-ABL1 is found in nearly all cases of CML and approximately one-third of the patients with BCR-ABL1 + ALL. Several studies using mouse models suggest that forced expression of BCR-ABL1 alone in hematopoietic stem cells can induce CML-like myeloproliferative disorder. However, cooperating oncogenic gene alterations are required for the generation of blastic leukemia (1, 2) . On the other hand, forced expression of BCR-ABL1 alone in human hematopoietic cells does not develop leukemia (3) . Since BCR-ABL1 + ALL is a more aggressive disease than CML, factors other than BCR-ABL1 are considered to be involved in its development and progression with decreased responses to the BCR-ABL1 tyrosine kinase inhibitors (TKIs) (4) . Yet the reasons for aggressive nature of BCR-ABL1 + ALL and molecular basis of transformation of CML into lymphoblastic crisis (CML-LBC) remain to be clarified.
In nearly a decade, several groups reported the expression of aberrant IKAROS isoforms in CML-LBC and BCR-ABL1 + ALL (5) (6) (7) . IKAROS is a zinc-finger nuclear protein that is essential for normal lymphoid development (8) (9) (10) . Mice homozygous for the Ikaros null allele lack B, NK, and prenatal T cells (11) , while T cell leukemia and lymphoma develop in mice heterozygous for the dominant-negative (DN) allele with 100% penetrance (12) . By alternative splicing, multiple IKAROS isoforms are generated, several of which, including IK6, lack the aminoterminal zinc fingers required for DNA binding (10, 13) . IK6 is normally expressed at very low levels, retaining the dimerization domain, but lacking the four amino-terminal DNA-binding zinc fingers. Therefore, IK6 shows a DN effect by titrating out the DNA-binding activities of other IKAROS isoforms (14) . (4, 17) . The knock-in mice expressing the DN Ikaros developed leukemia earlier than the control mice on mating with the BCR-ABL transgenic mice, with fewer additional chromosomal abnormalities (18) . These findings suggest that IK6 serves as second hit in BCR-ABL1-mediated leukemogenesis or vice versa. In addition, forced expression of IK6 in human B cells was reported to confer drug resistance (19) . Moreover, recent clinical studies revealed that the deletion of IKZF1 has negative prognostic impact in human ALL (20, 21) .
Although limited studies using human CD34 + cells demonstrated that BCR-ABL1 expression results in erythroid differentiation and expansion of erythroid progenitors (3, 22, 23) , the consequence of co-expression of IK6 and BCR-ABL1 in primary human hematopoietic cells has not hitherto been addressed.
To investigate whether IK6 collaborates with BCR-ABL1 in human hematopoietic cells, we examined the combinatory effect of BCR-ABL1 and IK6 on proliferation and differentiation of human CD34
+ hematopoietic progenitor cells in stroma-free culture or in co-culture with human stromal cells, which support not only myeloid but also early B cell differentiation, using retroviral vectors. Here we demonstrate a synergistic effect of IK6 and BCR-ABL1 in the growth of CD34 + progenitor cells, which is enhanced on human stromal cells.
Materials and methods
Cells and the cell line. Cord blood (CB) samples were collected from normal deliveries after obtaining written informed consent in accordance with guidelines from the human subject ethics committee at Mie University (No. 995). Mononuclear cells were separated by Ficoll-Hypaque centrifugation (Sigma Chemical Co., St. Louis, MO, USA). The CD34 + cells were enriched by two passages using immunoselection with the MACS CD34 Isolation Kit (Miltenyi Biotec, Auburn, CA, USA) as described previously (24) . The percentage of CD34 + cells was >95% by flow cytometry analysis after this procedure.
The telomerized human stromal cell line (25) was cultured in RPMI-1640 medium (Nacalai Tesque, Kyoto, Japan) with 10% fetal bovine serum (FBS) (Hyclone Laboratories, Logan, UT, USA) in the presence of antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin). The cells were incubated at 37˚C in a humidified atmosphere flushed with 5% CO 2 .
Construction of the plasmids. The complementary DNAs (cDNAs) for p190
BCR-ABL1 (B1A2) and p210 BCR-ABL1 (B3A2) (26) cloned in a pMXneo vector (27) (kindly provided by Dr Tsuyoshi Tanabe, Shimane University, Izumo, Japan) were inserted into an EcoRI site of a pMYs-IRES (internal ribosomal entry site)-EGFP (enhanced green fluorescent protein) retroviral vector (28) to generate pMYs-p190
BCR-ABL1 -IRES-EGFP and pMYs-p210
BCR-ABL1 -IRES-EGFP, respectively. The IK6 cDNA was obtained from Ph + human cell line BV173 (29) by reverse transcription (RT)-polymerase chain reaction (PCR) as described previously (19) . The IK6 cDNA was introduced between BamHI and NotI sites of pMYs-IRES-Kusabira Orange (KO) vector which is a derivative of pMXs-IRES-KO (30) , to generate pMYs-IK6-IRES-KO. The pMYs-IRES-EGFP (GFP mock) and pMYs-IRES-KO (KO mock) vectors were used as control vectors.
Retrovirus production and transduction of CB CD34
+ cells. Transfection of the retroviral vector and pCMV-VSV-G (kindly provided by Dr Hiroyuki Miyoshi, RIKEN, Tsukuba, Japan) into PLAT-gp cells (28) was carried out using FuGENE 6 (Roche Diagnostic Corp., Indianapolis, IN, USA) according to the manufacturer's recommendations. The retroviruses (pseudo-type) were harvested twice 48 and 72 h after transfection, passed through a 0.45-µm filter, concentrated by centrifugation at 6,000 g for 16 h, and resuspended in α-minimum essential medium (α-MEM), then stored at -80˚C until use for transduction.
For retroviral transduction, CB CD34 + cells were first stimulated for 48 h in α-MEM with 20% FBS and human thrombopoietin (TPO; 20 ng/ml), stem cell factor (SCF; 50 ng/ ml), and FLT3 ligand (FLT3-L; 50 ng/ml), which were purchased from PeproTech (Rocky Hill, NJ, USA), in 6-well plates. During the last 4 h of pre-stimulation, the virus stock was preloaded onto Retronectin (Takara, Otsu, Japan)-coated 24-well plate according to the manufacturer's recommendation as described (30) . The pre-stimulated cells resuspended in the fresh medium were transferred to the virus-loaded 24-well plate at a concentration of 1x10 5 cells/ml. The cells were cultured for another 48 h, and the transduction efficiency (positive rates of GFP and KO) was analyzed by flow cytometry.
Proliferation and differentiation assays. For stroma-free culture, 0.5x10 5 cells resuspended in 0.5 ml of the same fresh medium as that used in pre-stimulation were plated in duplicate in 24-well plates after 48 h of transduction and passaged thereafter before they reached confluence.
For stromal culture, the same post-transduced cells resuspended in the same medium as that for the stroma-free culture were plated onto the 25 cm 2 flask pre-sheeted with the semiconfluent human stromal cells, which support early B cell differentiation (Nakamori et al, unpublished data). The cells were fed twice a week by half medium change.
The cell numbers were counted by trypan blue dye exclusion at days 14 and 21 after isolation of CD34 + cells. To analyze immunophenotype of cultured cells, the cells were collected and their phenotype was assessed with flow cytometry at days 14 and 21 after isolation of CD34 + cells. Cytospin preparations were stained with Wright-Giemsa stain and viewed with a BX50F4 microscope (Olympus Optical, Tokyo, Japan) at magnification x400.
Assays using transwell plates. To test dependency on contacting to stromal cells in cell growth and survival, transwell plates (5 µm pores; Corning, NY, USA) were used. The 0.5x10 5 post-transduced cells were resuspended in the same medium described above, and were added onto the plate pre-sheeted with semi-confluent human stromal cells (lower compartment), or into transwell inserts (upper compartment) to avoid direct contact to the stromal cells. Thus the upper compartment separated with transwell membrane reflects the stroma-free culture condition with probable soluble factors from the stromal cells and the lower compartment is in stromal condition. RT-PCR. Total RNA was extracted from the cells and reverse transcribed to cDNA with random hexamers as described previously (31) . PCR amplification was run for 28 cycles. The condition and reagents for RT-PCR were previously described (31) using the following primers: p190
BCR-ABL1 -S, 5'-CTA TACCCCGGACTGCAGCT-3', and p190
BCR-ABL1 -AS, 5'-CCA GCGAGAAGGTTTTCCTTGGA-3' for the B1A2 p190 transcript, p210 BCR-ABL1 -S, 5'-GAGTCACTGCTGCTGC TTATGTCT-3', and p210
BCR-ABL1 -AS, 5'-CCAGCGAGAAGG TTTTCCTTGGA-3' for the B3A2 p210 transcript, IK6-S, 5'-CCCCTGTAAGCGATACTCCAGA-3', and IK6-AS, 5'-CTTGGAGAGCAGCAGCAGGTT-3' for the IK6 transcript.
Immunoprecipitation and Western blot analyses. Immunoprecipitation (IP) and Western blotting were performed as described previously (32) . In brief, PLAT-gp cells transfected with each construct were harvested with the lysis buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Noridet P-40, 1 mM EDTA, 0.2 mM Na 3 VO 4 , 2 mM phenylmethylsulfonyl fluoride]. Cell lysates for BCR-ABL1 detection were cleared of debris by centrifugation at 12,000 g for 30 min, and the supernatants were incubated with an anti-BCR monoclonal antibody G6 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4˚C for 2 h. Immune complexes were precipitated with protein G-Sepharose (Amersham Bioscience, Uppsala, Sweden), washed with the lysis buffer, and proteins were eluted with an SDS (sodium dodecyl sulfate) sample buffer [62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.02% bromophenol blue] for SDS-PAGE. Cell lysates for IK6 detection were directly mixed with an equal volume of 2X SDS sample buffer. The eluted proteins were electrophoresed and transferred to nitrocellulose. Membranes were probed with antibodies (the anti-BCR antibody G6 for BCR-ABL1 detection and an anti-IKAROS antibody E20 (Santa Cruz Biotechnology) for IK6 detection), and visualized with the enhanced chemiluminescence detection system (Amersham-Pharmacia, Orsay, France) as described previously (31) .
Statistical analyses. Data were analyzed for significance between groups using a Mann-Whitney U test. All differences were considered significant at p<0.05.
Results

Transduction and expression of BCR-ABL1 and IK6 in human CD34
+ cells. To investigate how co-expression of BCR-ABL1 and IK6 affects proliferation and differentiation of human CD34 + hematopoietic progenitors, BCR-ABL1 and/or IK6 were retrovirally introduced into the CD34 + cells using bicistronic retroviral vectors encoding GFP (BCR-ABL1) or KO (IK6). The experimental schemes are summarized in Fig. 1A (Fig. 1C) . Furthermore, RT-PCR analysis of total RNA from transduced CD34 + cells verified the transgene expression (Fig. 1D) .
IK6 enhances proliferative effects by BCR-ABL1 in human CD34
+ cells. -control cells (n=7; Fig. 2B ). We next analyzed the immunophenotype of each cell fraction at day 21 after transduction in stroma-free culture (Fig. 3A) . As previously reported (23) megakaryocytic cells with multilobulated nuclei (Fig. 3B) 
Co-expression of BCR-ABL1 and IK6 in human CD34
+ cells leads to erythroid cell expansion even by co-cultures with human stromal cells which support early B cell differentiation. We next examined the effects of IK6 and BCR-ABL1 on the proliferation and differentiation of hematopoietic progentiors by co-culture with telomerized human stromal cells that support myeloid and early B cell development. We observed that non-transduced CD34 + cells gave rise to ~15-20% of CD19 + B lymphoid precursors, following 3 weeks of culture (Fig. 4A) . However, the CD34 + cells expressing p210 or p190 failed to generate CD19 + B-lineage cells (Fig. 4B) Other immunophenotypes regarding to the expression of CD34, CD14, CD15 (data not shown), and CD41 were almost similar to those in stroma-free culture (Figs. 3A and 4B) . Thus, co-expression of BCR-ABL1 and IK6 in human CD34 + cells mainly leads to erythroid cell expansion even in the circumstances that support early B cell differentiation.
Notably, we observed that the synergistic growth-promoting effects between IK6 and p190 BCR-ABL1 became more remarkable in stromal culture, compared with the findings obtained with stroma-free culture (Fig. 5) .
Synergistic effect of BCR-ABL1 and IK6 on cell proliferation is enhanced by co-cultures with stromal cells.
To compare the co-operativity of BCR-ABL1 and IK6 between stroma-free and stromal cultures, GFP/KO-double positive rates were analyzed from the aspect of growth advantage. The percentages of the BCR-ABL1 + /IK6 + populations were significantly higher than those of the BCR-ABL1 + /IK6 -populations in stromal culture (Fig. 6C and D) , while statistically not in stroma-free culture in seven independent experiments (Fig. 6A  and B) . Nevertheless, the p210 + /IK6 + population in stroma-free culture also showed tendency of higher growth than the p210 + / IK6 -population (Fig. 6B) , albeit not so much in the p190 + / IK6 + population (Fig. 6A) . Therefore, the outgrowth driven by BCR-ABL1 and IK6 in stromal culture relative to stroma-free culture is prominent in p190, but not in p210 (p=0.010 and 0.365, respectively; Fig. 7 ). These findings indicate that the co-operation between IK6 and BCR-ABL1, especially p190, to stimulate cell proliferation is enhanced on stromal cells.
Growth enhancement by co-expression of BCR-ABL1 and IK6 on stromal cells requires cell adhesive interaction.
During the cell culture experiments, we noticed that a higher proportion of the cells transduced with BCR-ABL1 adhered to the stromal cells compared with the control cells (data not shown). Therefore, we investigated whether direct cell to cell interaction between transduced hematopoietic progenitors and stromal cells is required for the synergistic effect of BCR-ABL1 and IK6 on cell proliferation by using transwell plates. To this end, the percentages of the BCR-ABL + /IK6 + cell population and of the BCR-ABL1 + /IK6 -cell population in both upper and lower compartments were analyzed at day 21 after CD34 + separation. The percentages of the BCR-ABL1 + /IK6 + cell populations were increased significantly in lower compartment, albeit not in upper compartment (Fig. 8) . However, the percentages of BCR-ABL1 + /IK6 -cell populations were not significantly different in upper and lower compartments in three independent experiments. These results suggest that the enhanced cell proliferation induced by BCR-ABL1 and IK6 in stromal culture is mediated by direct cell adhesive interaction rather than the soluble factors produced by the stromal cells. BCR-ABL1 and IK6 in stromal culture was excluded because the transduction itself was unsuccessful. Open circles represent the averages in each panel.
Discussion
In this study we demonstrated the synergistic effect of BCR-ABL1 and IK6 on cell proliferation and differentiation in human CD34
+ cells, and that this effect was enhanced on stromal cells, especially between p190 and IK6.
Forced expression of BCR-ABL1 and that of IK6 in human CD34 + cells were reported to induce erythroid cell expansion and to impair B cell differentiation, respectively (10, 22, 23) .
Despite the use of human, not murine stromal cells which can support early B cell development, expression of BCR-ABL1 and IK6 in human CD34 + cells resulted in GPA + erythroid cell expansion and inhibition of B cell differentiation. Notably, major populations of the cells transduced with both BCR-ABL1 and IK6 expressed GPA and CD41. These findings led us to speculate that coexpression of BCR-ABL1 and IK6 induced the growth of more immature progenitors with both erythroid and megakaryocytic differentiation potentials. Although precise mechanism remains to be elucidated, impaired IKAROS function may perturb the differentiation of hematopoietic progenitors that have proliferative and/or survival advantage by BCR-ABL1-mediated signaling. Interestingly, IKAROS was recently reported to behave as tumor suppressor to induce cell cycle arrest in BCR-ABL1 + cells through cooperation with downstream molecules of the pre-B cell receptor signaling pathway, and this effect is reversed by coexpression of IK6 (33) .
The synergistic effect was greatly enhanced on stromal cells in our experiments. The assays using transwell plates suggested that the co-operative effect depends on cell adhesive interaction of hematopoietic progenitors and stromal cells. The bone marrow stromal microenvironment may provide anti-apoptotic signals to the leukemic cells. Indeed in clinical observations, TKIs-resistant cells from relapsed patients are still sensitive to the proapoptotic effects of TKIs when administrated ex vivo (34) . Further study may uncover the role of stromal microenviroment in leukemogenesis of Ph + ALL with impaired IKAROS function.
To date, strong clinical evidence exists supporting the idea that BCR-ABL1 and impaired IKAROS function play pivotal roles in BCR-ABL1-related aggressive lymphoid leukemogenesis. However, these 'two hits' are unlikely to be sufficient to fully transform human CD34 + cells in vitro, because CD34 + cells were not immortalized after transduction in our experimental systems (data not shown). It is plausible that additional key players are required to recapitulate BCR-ABL1-related human lymphoid leukemia. Yet preferential co-operation of IK6 and p190, not p210 on stromal cells may partly reflect the rarity of p190 in human CML.
Although it is challenging to study the effect of coexpression of BCR-ABL1 and IK6 in human CD34 + cells transplanted into immunodeficient mice (3, 23) , it could unveil the long-term effects of BCR-ABL1 and IK6 in human cells under in vivo conditions. However, we have been unable to achieve promising results at present. Further trial on different target cells, and/or introduction of additional molecules is necessary to solve this important issue.
In conclusion, we found that the co-operativity between BCR-ABL1 and IK6 was enhanced in primary human CD34 + cells through direct interaction with human stromal cells, especially between p190 and IK6. These findings would provide a clue to elucidate the mechanism of lymphoid leukemogenesis by BCR-ABL1, and also the mechanism underlying the difference of the disease phenotype between p190
BCR-ABL1 and p210 BCR-ABL1 . Further studies are required to see whether IK6 controls BCR-ABL1 expression and activity during disease progression, and how IK6 influences the survival and self renewal of the BCR-ABL1 + leukemia-initiating cells in the bone marrow microenvironment.
